MarketCap
Facebook
X
TelegramPRA Health Sciences, Inc. Revenue 2011-2026 | PRAH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue PRA Health Sciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 3.18 B | 3.07 B | 2.87 B | 2.26 B | 1.81 B | 1.61 B | 1.46 B | - | 700 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.18 B | 700 M | 2.12 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
6.32 B | $ 115.19 | 0.1 % | $ 35 B |  USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.14 | 0.44 % | $ 6.21 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 16.2 | 0.56 % | $ 174 M |  China |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 16.29 | 1.46 % | $ 868 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.41 | 2.92 % | $ 1.88 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 2.25 | -2.17 % | $ 9.95 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 23.05 | -0.35 % | $ 640 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 175.38 | -0.17 % | $ 8.69 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 498.64 | 1.04 % | $ 14.4 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 190.7 | 0.6 % | $ 136 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.47 | 2.64 % | $ 414 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 122.51 | 1.3 % | $ 19.5 B | USA |
 |
NeoGenomics
NEO
|
727 M | $ 7.94 | 3.19 % | $ 1.02 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 14.95 | 3.57 % | $ 452 M | USA |
 |
Guardant Health
GH
|
982 M | $ 78.76 | 0.2 % | $ 9.87 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.77 | 2.97 % | $ 89.9 K | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.07 | -3.19 % | $ 4.75 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 28.27 | -0.12 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 107.75 | 0.88 % | $ 8.89 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 261.97 | 0.4 % | $ 21.8 B | USA |
 |
Natera
NTRA
|
820 M | $ 199.83 | 3.52 % | $ 19.7 B | USA |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 6.67 | -0.15 % | $ 278 M | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 80.99 | 0.5 % | $ 5.47 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 192.07 | 0.29 % | $ 21.3 B | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | $ 52.58 | -0.1 % | $ 2.67 B | USA |
 |
Neogen Corporation
NEOG
|
895 M | $ 9.19 | -2.46 % | $ 1.99 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 5.0 | 1.21 % | $ 3.94 M | USA |
 |
Organovo Holdings
ONVO
|
144 K | - | -2.3 % | $ 19.4 M | USA |